



Prospective Cohort Study of Oral Health Promotion Program for Head and Neck Cancer Patients Receiving Radiotherapy



Eunji Kim¹, Hong-Gyun Wu¹, Jin Ho Kim¹, Hye-Ju Lee², Dong-Hun Han²

¹Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea

²Department of Preventive and Social Dentistry, Seoul National University College of Dentistry, Seoul, Korea

Introduction

- Head and neck cancer (HNC) patients not only have to face a life-threatening disease, but also have to deal with the impact of the disease and its treatment.
 - eg. oral pain, xerostomia, dysgeusia, osteoradionecrosis, trismus
- Treatment strategies are aimed
 - Increasing the chances of cure
 - Maintaining health-related quality of life
- Previous studies on oral health care program for HNC patients receiving radiotherapy (RT)
 - Chlorhexidine mouth rinse (USA, 1990)
 - Oral care analgesic treatment (USA, 1992)
 - Antibiotic pastile (UK, 1996)
 - Tantum mouth rinse (Iran, 2009)
 - Fluoride varnish (India, 2013)**
 - Topically applied fluorides buffers pH of saliva and remineralizes tooth structure.

Purpose

- To develop and evaluate oral health promotion program to improve the quality of life of the HNC patients receiving RT

Methods

Open-label, non-randomized, prospective study

Accrual period: Jan. 2014 - June. 2015

Inclusion criteria


- Written informed consent
- Pathologically confirmed HNC
- Major salivary glands and oral mucosa included in the high-dose radiation field

Exclusion criteria


- Moderate-severe dental disease
- Medication such as anticholinergics, steroids and antihistamines

	Pre & during RT	Post-RT	3-month f/u	6-month f/u
Control group	Exam Questionnaire	Questionnaire	Exam Questionnaire	Exam Questionnaire
Experimental group	Exam Questionnaire Education	Questionnaire	Exam Questionnaire Education	Questionnaire
	Fluoride varnish	Fluoride varnish	Fluoride varnish	Fluoride varnish

Fluoride gargle and varnish



Results



Results: patient characteristics

Characteristics	Control (n=30)	Experimental (n=31)	P
Age (years, range)	60 (21-79)	58 (18-81)	
Gender	Male Female	17(56.7) 13(43.3)	19(61.3) 12(38.7)
Education	≤ Middle school Highschool ≥ College	9(30.0) 14(46.7) 7(23.3)	6(19.4) 11(35.5) 14(45.2)
Occupation	Unemployed White collar Blue collar	15(50.0) 7(26.7) 8(23.3)	14(45.2) 10(32.3) 7(22.6)
Smoking history	Non-smoker Ex-smoker Smoker	15(50.0) 14(46.7) 1(3.3)	16(51.6) 11(35.5) 4(12.9)
Tumor site	Oropharynx Nasopharynx Oral cavity Hypopharynx Others	8(26.7) 4(13.3) 6(20.0) 4(13.3) 8(26.7)	9(29.0) 6(19.4) 5(16.1) 2(6.5) 9(29.0)
AJCC stage	I,II III IV	3(10.0) 10(33.3) 17(56.7)	7(24.1) 9(31.0) 13(44.8)
RT aim	Radical Postoperative	16(53.3) 14(46.7)	15(48.4) 16(51.6)
RT dose (Gy, range)	67.5 (54-67.5)	63 (58.5-72)	
CCRT	Yes No	20(66.7) 10(33.3)	15(48.4) 16(51.6)
			0.198

➤ There was no difference in patient characteristics between two groups.

Changes of EORTC QLQ-H&N35, OH17

EORTC QLQ-H&N 35 indices	Control		Experimental		P
	Before	6month f/u	Before	6month f/u	
Total	24.09(13.18)	31.64(19.51)	25.99(15.34)	24.11(14.45)	0.075
Scales					
Pain	18.52(13.82)	26.07(26.76)	20.29(18.14)	17.47(13.15)	0.093
Swallowing	12.04(15.80)	21.77(25.28)	20.53(24.26)	16.93(19.61)	0.054
Senses	13.89(24.07)	27.96(28.67)	14.82(23.09)	17.74(21.49)	0.606
Speech	18.83(20.71)	27.60(27.79)	17.63(21.41)	12.54(17.52)	0.179
Social eating	19.44(25.59)	34.94(32.59)	26.14(31.55)	22.31(24.00)	0.065
Social contact	19.63(23.25)	23.65(30.25)	15.80(20.97)	13.98(23.75)	0.263
Sexuality	12.38(17.78)	28.16(32.76)	23.33(33.97)	20.43(27.12)	0.045
Single items					
Teeth problems	37.14(36.84)	35.55(34.94)	28.26(31.40)	21.50(30.48)	0.517
Open mouth	25.92(32.96)	45.55(34.44)	25.36(34.56)	26.88(31.53)	0.129
Dry mouth	33.33(29.81)	51.61(32.01)	34.81(32.53)	54.83(31.68)	0.201
Sticky saliva	22.22(26.42)	38.71(32.31)	22.96(30.00)	41.11(33.54)	0.857
Cough	19.44(18.47)	18.28(25.58)	20.29(22.75)	20.00(27.12)	0.980
Weight loss	41.18(49.96)	45.16(50.59)	50.00(50.55)	38.71(49.51)	0.303
Weight gain	14.29(35.50)	25.81(44.48)	13.04(34.05)	29.03(46.14)	0.168
Nutritional supplements	34.29(48.16)	32.26(47.52)	36.96(48.80)	41.94(50.16)	0.636
Use of feeding tube	17.14(38.24)	12.90(34.08)	17.39(38.32)	6.45(24.97)	0.775
Use of pain killers	60.00(49.71)	45.16(50.59)	56.52(50.12)	16.13(37.39)	0.049
Feeling ill	16.67(23.23)	27.95(33.44)	21.48(29.43)	13.98(20.68)	0.188

EORTC QLQ-OH 17 indices	Control		Experimental		P	
	Before	6month f/u	P	Before	6month f/u	
Total	23.62(14.48)	29.25(12.57)	0.017	23.71(11.09)	15.13(13.50)	<0.001
Scales						
Pain/discomfort	17.03(18.03)	18.75(20.14)	0.606	8.00(7.97)	8.25(13.11)	0.907
Xerostomia	26.44(22.94)	46.55(27.95)	0.005	23.33(24.60)	48.33(31.36)	<0.001
Eating	24.19(20.68)	31.72(28.00)	0.144	20.96(21.66)	18.94(22.37)	0.654
Information	56.54(15.93)	61.90(17.48)	0.248	60.21(17.57)	62.36(14.25)	0.619
Single-item questions						
Worm dentures	3.45(10.33)	3.45(10.33)	1.000	1.39(6.73)	0.69(4.81)	0.569
Ill-fitting denture	8.05(22.98)	10.34(28.31)	0.489	5.56(19.85)	1.39(6.73)	0.159
Worried about future	36.78(43.04)	34.48(39.32)	1.745	38.19(35.72)	11.80(22.27)	<0.001

➤ Total score of OH17 indices was significantly improved in experimental group.

Subgroup analysis: EORTC H&N 35

	Swallowing	Senses	Speech	Social eating	Social contact	Sexuality	Teeth problems	Dry mouth	Use of pain killers
Age	< 60 yr	0.384	0.888	0.114	0.874	0.526	0.118	0.922	0.237
	≥ 60 yr	0.138	0.092	0.357	0.040	0.170	0.015	0.272	0.397
Stage	I-III	0.582	0.910	0.753	0.434	0.932	0.458	0.587	0.747
	IV	0.069	0.346	0.054	0.099	0.359	0.001	0.377	0.710
CCRT	CCRT	0.150	0.955	0.093	0.094	0.482	0.032	0.047	0.808
	RT alone	0.089	0.033	0.613	0.554	0.660	0.193	0.346	0.879
RT	Radical	0.037	0.804	0.190	0.270	0.404	0.033	0.037	0.668
</td									